Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2017 07:00 ET | Source: Insys Therapeutics, Inc.

Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs

PHOENIX, April 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that effective today, Dr. Steven James will join the Company as Vice President...
April 03, 2017 06:50 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results

PHOENIX, April 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December...
March 27, 2017 07:00 ET | Source: Insys Therapeutics, Inc.

Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017

PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the...
March 23, 2017 07:33 ET | Source: Insys Therapeutics, Inc.

DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final...
March 15, 2017 16:30 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results

PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the Company will delay the release of its financial results for the...
March 02, 2017 09:18 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results

PHOENIX, March 02, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter...
February 15, 2017 07:00 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study

CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral...
February 14, 2017 16:30 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference

PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and...
January 09, 2017 06:50 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board

PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive...
January 04, 2017 16:30 ET | Source: Insys Therapeutics, Inc.

Insys Therapeutics, Inc. to Present at J.P. Morgan 35th Annual Healthcare Conference

PHOENIX, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical...